UNICREDIT BANK/PUT/ELI LILLY & CO/1000/0.1/18.06.25 Share Price

Warrant

DE000HD4FMV9

Market Closed - BOERSE MUENCHEN 01:10:23 28/06/2024 am IST
13.85 EUR -1.14% Intraday chart for UNICREDIT BANK/PUT/ELI LILLY & CO/1000/0.1/18.06.25
Current month-26.84%
1 month-28.20%
Date Price Change
27/24/27 13.85 -1.14%
26/24/26 14.01 +0.21%
25/24/25 13.98 -2.85%
24/24/24 14.39 -3.16%
21/24/21 14.86 -1.39%

Real-time BOERSE MUENCHEN

Last update June 28, 2024 at 01:10 am IST

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying ELI LILLY AND COMPANY
IssuerLogo Issuer UniCredit UniCredit
WKN HD4FMV
ISINDE000HD4FMV9
Date issued 08/04/2024
Strike 1,000 $
Maturity 18/06/2025 (356 Days)
Parity 10 : 1
Emission price 21.68
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 26.53
Lowest since issue 13.81
Delta-0.54x
Omega 3.353
Premium6.02x
Gearing6.24x
Moneyness 1.100
Difference Strike 90.96 $
Difference Strike %+9.10%
Spread 0.1
Spread %0.73%
Theoretical value 13.61
Implied Volatility 31.49 %
Total Loss Probability 37.96 %
Intrinsic value 8.498
Present value 5.112
Break even 854.32 €
Theta-0.07x
Vega0.32x
Rho-0.34x

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
More about the company

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Eli Lilly and Company

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
909 USD
Average target price
860.5 USD
Spread / Average Target
-5.33%
Consensus